Friday, March 20, 2026Fri, Mar 20, 2026

TrendingNews.today

S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|

S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|

Health1 sourcesNeutral

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016

This milestone brings another innovative bispecific ADC from the company's pipeline into pivotal development

Alphamab Oncology

via Alphamab Oncology

March 20, 2026 | 12:00 AM UTCUpdated 2h ago

Share Read original

Read the full article at Alphamab Oncology →

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Alphamab Oncology

Comments

0 comments

Be respectful and constructive.

Loading comments...

Inch 4K+ Programming Monitor Helps Reduce Eye Strain

King Seiko Updates the Vanac in Titanium

Related Articles

Eledon Pharma FY25 Net Loss Widens; Tegoprubart Phase 3 Development On Track In Kidney Transplant

Unknown-4h ago-1 sources

Oil Prices Edge Higher After Drone Attack Targeting Kuwait Oil Refinery

Unknown-4h ago-2 sources

TUHU Car Inc. Reveals Fall In Full Year Profit

Unknown-4h ago-1 sources